CSL Confirms Supply Halt for Hemgenix Amid Manufacturing Challenges

CSL Behring suspends global Hemgenix deliveries due to production scaling issues, impacting hemophilia B patients as competitors exit. The firm maintains 2026 guidance amid a strategic reset.

CSL Behring has confirmed a worldwide suspension of deliveries for its gene therapy Hemgenix. The company cites significant hurdles in scaling up the complex manufacturing process as the reason for the supply constraint. This development is particularly critical for the hemophilia B treatment landscape, as competitors including Pfizer and BioMarin have recently exited the market, leaving CSL as the sole supplier.

Strategic Overhaul Pressures Profitability

The current fiscal year is being described by management as a "reset" period. CSL is undergoing a substantial transformation, which involves shuttering unprofitable plasma collection centers and consolidating its research sites from eleven down to six. While the core plasma business is showing volume growth again, a strategy to regain market share through pricing is applying short-term pressure on gross margins.

Despite these operational headwinds, the company is maintaining its fiscal 2026 guidance. It expects currency-adjusted net profit after tax amortization (NPATA) to grow between 4% and 7%. Management has indicated that a sustainable recovery in earnings is anticipated for the following year, 2027.

Stock Buyback Amid Share Price Volatility

These operational issues coincide with a volatile market environment. CSL shares hit a new 52-week low of €82.33 last Thursday but managed a slight recovery to close the week at €83.73 on Friday. In a move to support the equity price, the company is continuing its share repurchase program, which is authorized for up to $750 million. To date, this plan has already seen the buyback of more than 4.4 million shares.

Production Bottlenecks, Not Safety Concerns

According to a company statement dated March 21, 2026, the supply chain interruption is not related to any concerns about the product's safety or efficacy. Instead, the biotech firm is grappling with bottlenecks in its specialized manufacturing operations. In key markets such as the United States, where CSL now plays a pivotal role, this is resulting in delays for patient treatments. Company leadership is currently working with regulatory authorities to stabilize production output.